|
Dr.Tollefson was appointed to the Board of Directors in March 2004. A Distinguished Visiting Lilly Research Scholar and Clinical Professor of Psychiatry at the Indiana University School of Medicine, he brings to Cortex�s Board vast experience in neuroscience and significant business accomplishments at Eli Lilly & Company, playing a key strategic role in its blockbuster antidepressant and antipsychotic drugs Prozac� and Zyprexia�, respectively. Dr. Tollefson�s career highlights include having served as Distinguished Lilly Research Scholar and Vice President Medical-Neuroscience; President, Neuroscience Products and Vice President, Lilly Research Laboratories.He joined Eli Lilly & Company in June 1991 as an Executive Director of Lilly Research Laboratories with responsibility for Prozac�. He then assumed responsibility for the global medical planning of CNS drug development from Phase I through post marketing studies. Dr. Tollefson has also been actively involved with the FDA�s Neuropsychopharmacology Division with Lilly�s CNS products including: Cymbalta�, a new antidepressant; Symbiax�, a new treatment for bipolar depression; Zyprexa�, the top selling antipsychotic; Strattera�, a new treatment for Attention Deficit Hyperactivity Disorder; and multiple product-line extensions. Dr. Tollefson was Chairman of the Department of Psychiatry, St. Ramsey Medical Center, a University of Minnesota Teaching Affiliate Hospital. He received his B.S (Psychology), M.D. and Ph.D. (Psychopharmacology) from the University of Minnesota. Dr. Tollefson has authored or co-authored over 190 peer-reviewed scientific publications and been awarded 22 method of treatment patents. | 